Prescription ·Strong evidence ·Reviewed May 2026
Quinapril is an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension and, as adjunctive therapy, heart failure. It is a prodrug that is hydrolyzed to its active metabolite quinaprilat. By lowering angiotensin II levels it reduces vascular resistance and blood pressure.
The bottom line
Evidence rating strong. Most-documented uses: hypertension, heart failure (adjunctive). 3 sources indexed (2017), with 6 interaction records on file.
Core mechanism
Quinapril is a prodrug rapidly de-esterified to quinaprilat, which competitively inhibits angiotensin-converting enzyme (ACE). Blocking ACE prevents the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, lowering systemic vascular resistance and reducing aldosterone secretion, which decreases sodium and water retention. ACE inhibition also slows the degradation of bradykinin, contributing to vasodilation and to characteristic effects such as cough. The net result is reduced blood pressure and decreased cardiac afterload.1,2
Can be taken with or without food, though a high-fat meal may modestly reduce the rate and extent of absorption. Magnesium- and aluminum-containing antacids and tetracycline can reduce quinapril absorption, so separate dosing by at least 2 hours. Renal impairment prolongs exposure to the active metabolite and warrants dose reduction.2,3
Nutrients this medication can lower over time, and what to replace.
ACE inhibitors, including quinapril, contain or form sulfhydryl-related chelating chemistry and increase urinary zinc excretion, which over time can lower plasma and tissue zinc concentrations. Chronic ACE-inhibitor therapy has been associated with hyperzincuria and modest reductions in zinc status.
Potassium supplements or potassium-containing salt substitutes can cause hyperkalemia with Quinapril.
Recommendation: Avoid unsupervised potassium supplementation; check potassium and kidney function after initiation, dose changes, or illness.
Magnesium Glycinate may add to the blood-pressure-lowering effect of Quinapril.
Recommendation: Monitor blood pressure and dizziness, especially during dose changes; stop the supplement and seek advice if syncope, falls, or symptomatic hypotension occurs.
L-Citrulline may add to the blood-pressure-lowering effect of Quinapril.
Recommendation: Monitor blood pressure and dizziness, especially during dose changes; stop the supplement and seek advice if syncope, falls, or symptomatic hypotension occurs.
ACE inhibitors such as quinapril reduce aldosterone secretion, which decreases urinary potassium excretion and raises serum potassium. Adding supplemental potassium (or potassium-based salt substitutes) can produce clinically significant or dangerous hyperkalemia, particularly in patients with chronic kidney disease, diabetes, heart failure, or those also taking potassium-sparing diuretics, aldosterone antagonists, NSAIDs, or ARBs.
Recommendation: Avoid routine potassium supplements and potassium-containing salt substitutes while taking quinapril unless prescribed and monitored. If supplementation is medically necessary, use the lowest effective dose with periodic serum potassium and renal function checks. Report symptoms such as muscle weakness, palpitations, or numbness.
Quinapril tablets contain magnesium carbonate as an excipient, and concurrent magnesium- or aluminum-containing antacids (and to a lesser extent oral magnesium supplements taken at the same time) can reduce quinapril absorption by forming poorly soluble chelates in the gut, potentially lowering its blood-pressure-lowering effect. The interaction is well documented for magnesium-containing antacids; separating administration restores absorption.
Recommendation: Separate oral magnesium supplements from quinapril by at least 2 hours to minimize any reduction in drug absorption. Take quinapril consistently with respect to meals and monitor blood pressure if you begin or change magnesium dosing.
Oral iron salts can chelate ACE inhibitors in the gastrointestinal tract, and quinapril's magnesium carbonate formulation may also reduce iron absorption when taken together. Co-administration risks lowering the bioavailability of both agents. Data are clearer for related ACE inhibitors, but the chelation mechanism is shared.
Recommendation: Separate oral iron supplements from quinapril by at least 2 hours. Monitor blood pressure and, if treating iron deficiency, recheck iron studies to confirm adequate response.
Numbered references. Citations throughout the page link here.
ACE inhibition reduces aldosterone, decreasing renal potassium excretion and raising hyperkalemia risk; periodic serum potassium and renal function monitoring is recommended.
Quinapril lowers blood pressure via ACE inhibition; usual hypertension dose is 10-80 mg daily, with dose reduction in renal impairment and monitoring for hyperkalemia and angioedema.
Coadministration of magnesium/aluminum hydroxide antacids reduces the extent of quinapril absorption; doses should be separated.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
